基于人抗菌肽LL-37探索溃结宁方治疗溃疡性结肠炎的作用机制

To explore the mechanism of action of antibacterial peptide LL-37 Kui Jie Ningdecoction "in the treatment of ulcerative colitis based

目的：探讨基于人抗菌肽LL-37在溃结宁方治疗溃疡性结肠炎中的作用机制。方法：选择我院2012年1月～2014年6月收治的溃疡性结肠炎患者30例作为观察组，分析患者使用中药后LL-37指标的变化，分析患者人抗菌肽LL-37治疗溃疡性结肠炎的作用机制。结果：治疗前UC患者结肠黏膜中LL-37、TNF-α、IL-1β、IL-4等水平相对较高，治疗后患者LL-37水平为（4.97±6.95）、TNF-α为（97.04±23.74）、IL-1β为（72.98±38.03）、IL-4为（26.04±12.47），均明显低于治疗前（P〈0.05）。结论：LL-37在UC患者的结肠黏膜中表达增强，能够作为溃疡性结肠炎患者的治疗指标。

Objective： To investigate the antimicrobial peptide LL-37 in the mechanism of action of Kuijie Ning decoction in treating ulcerative colitis based.Methods：In our hospital in 2012 January -2014 year in June were ulcerativecolon 30 cases as the study group ,the changes of pa-tients with the use of traditional Chinese medicine after LL-37 index analysis ,mechanism analysis of patients with human antimicrobial peptide LL-37 in the treatment of ulcerative colitis.Results： before treatment,the colonic mucosa of patients with UC in LL-37,TNF- alpha,IL-1 be-ta,IL-4 level is relatively high,LL-37 levels after treatment in patients with as（4.97±6.95）,TNF-（97.04±23.74）alpha,IL-1 beta is（72.98± 38.03）,IL-4 （26.04±12.47）,were lower than the treatment the former （P〈0.05）.Conclusion：the enhanced expression of LL-37 in colonic mu-cosa of UC patients,can be used as a therapeutic index in patients with ulcerative colitis.